AKTIV: Changes in Physical Functioning in Patients With COPD During Therapy With a Combination of Spiriva® Respimat® + Striverdi® Respimat® or Spiriva® 18 Mikrogramm + Striverdi® Respimat®
AKTIV: Changes in Physical Functioning in Patients With COPD During Therapy With a Combination of Spiriva® Respimat® + Striverdi® Respimat® or Spiriva® 18 Mikrogramm + Striverdi® Respimat®
The decrease in physical activity due to increasing dyspnoea that over time leads to a steadily worsening condition and increasing restriction of physical functioning is a key problem for COPD patients and affects even the early stages.
Clinical studies to investigate both Spiriva® and Striverdi® Respimat® have demonstrated a marked improvement in physical exercise capacity.
However, there have so far been no data from the daily practice setting about everyday functioning on combination treatment with Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Mikrogramm plus Striverdi® Respimat® in patients requiring treatment with 2 long-acting bronchodilators.
The objective of this NIS is to measure changes in physical functioning as a surrogate for physical activity and exercise capacity in COPD patients on treatment with Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Mikrogramm plus Striverdi® Respimat® in routine daily treatment (so-called real life setting).
Inclusion criteria:
Exclusion criteria:
Bad Friedrichshall, Germany
Berkatal-Frankershausen, Germany
Bernkastel, Germany
Ehrenkirchen, Germany
Essen-Werden, Germany
Gailsdorf, Germany
Gräfeling, Germany
Heinsberg-Karken, Germany
Homburg/Saar, Germany
Hummeltal, Germany
Irsch/Saar, Germany
Kirchheim/Teck, Germany
Köln-Lindenthal, Germany
Lahnau, Germany
Mannheim - Vogelstang, Germany
Mühldorf/Inn, Germany
Mühlmein Am Main - Lämmerspiel, Germany
Sobernheim, Germany
Stadland-Schwei, Germany
Winhönng, Germany
Wolfsburg - Fallersleben, Germany
Zellertal, Germany